Camilla Zecchetto

1.4k total citations · 1 hit paper
28 papers, 856 citations indexed

About

Camilla Zecchetto is a scholar working on Oncology, Molecular Biology and Surgery. According to data from OpenAlex, Camilla Zecchetto has authored 28 papers receiving a total of 856 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Oncology, 12 papers in Molecular Biology and 8 papers in Surgery. Recurrent topics in Camilla Zecchetto's work include Pancreatic and Hepatic Oncology Research (16 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (6 papers) and Cancer Genomics and Diagnostics (5 papers). Camilla Zecchetto is often cited by papers focused on Pancreatic and Hepatic Oncology Research (16 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (6 papers) and Cancer Genomics and Diagnostics (5 papers). Camilla Zecchetto collaborates with scholars based in Italy, Spain and France. Camilla Zecchetto's co-authors include Davide Melisi, Valeria Merz, Raffaela Santoro, Francesca Simionato, Geny Piro, Giampaolo Tortora, Carmine Carbone, Antoine Hollebecque, Ian M. Silverman and Hui‐Ling Zhen and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Clinical Cancer Research.

In The Last Decade

Camilla Zecchetto

27 papers receiving 851 citations

Hit Papers

Clinicogenomic Analysis of FGFR2 -Rearranged Cholangiocar... 2020 2026 2022 2024 2020 50 100 150
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Clinicogenomic Analysis of FGFR2 -Rearranged Cholangiocarcinoma Identifies Correlates of Response and Mechanisms of Resistance to Pemigatinib
    2020 191 citations Ian M. Silverman, Antoine Hollebecque et al. Cancer Discovery profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Camilla Zecchetto Italy 12 417 376 254 196 138 28 856
Valeria Merz Italy 16 445 1.1× 353 0.9× 159 0.6× 186 0.9× 179 1.3× 36 851
Francesca Simionato Italy 17 455 1.1× 290 0.8× 125 0.5× 199 1.0× 199 1.4× 31 794
Alexandros Nomikos Greece 16 348 0.8× 232 0.6× 201 0.8× 180 0.9× 114 0.8× 29 649
Min Tu China 19 391 0.9× 486 1.3× 157 0.6× 321 1.6× 107 0.8× 43 928
Cinzia Puppin Italy 23 369 0.9× 782 2.1× 99 0.4× 220 1.1× 103 0.7× 46 1.2k
Moubin Lin China 16 413 1.0× 333 0.9× 288 1.1× 218 1.1× 145 1.1× 54 978
Caisheng Ye China 17 237 0.6× 494 1.3× 167 0.7× 282 1.4× 91 0.7× 29 976
William O’Connor United States 11 303 0.7× 621 1.7× 169 0.7× 249 1.3× 139 1.0× 28 998
Brett H. Herzog United States 12 631 1.5× 333 0.9× 130 0.5× 112 0.6× 116 0.8× 17 1.1k

Countries citing papers authored by Camilla Zecchetto

Since Specialization
Citations

This map shows the geographic impact of Camilla Zecchetto's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Camilla Zecchetto with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Camilla Zecchetto more than expected).

Fields of papers citing papers by Camilla Zecchetto

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Camilla Zecchetto. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Camilla Zecchetto. The network helps show where Camilla Zecchetto may publish in the future.

Co-authorship network of co-authors of Camilla Zecchetto

This figure shows the co-authorship network connecting the top 25 collaborators of Camilla Zecchetto. A scholar is included among the top collaborators of Camilla Zecchetto based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Camilla Zecchetto. Camilla Zecchetto is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Melisi, Davide, Monica Valente, Anna Maria Di Giacomo, et al.. (2024). Safety and clinical efficacy of IOA-289, a novel autotaxin inhibitor, plus gemcitabine and nab-paclitaxel (GnP) in patients with previously untreated metastatic pancreatic ductal adenocarcinoma (mPDAC).. Journal of Clinical Oncology. 42(16_suppl). e15130–e15130. 2 indexed citations
3.
Pietrobono, Silvia, et al.. (2024). CCL3 predicts exceptional response to TGFβ inhibition in basal-like pancreatic cancer enriched in LIF-producing macrophages. npj Precision Oncology. 8(1). 246–246. 4 indexed citations
4.
5.
Pietrobono, Silvia, Federica Fazzini, Valeria Merz, et al.. (2023). Autotaxin Secretion Is a Stromal Mechanism of Adaptive Resistance to TGFβ Inhibition in Pancreatic Ductal Adenocarcinoma. Cancer Research. 84(1). 118–132. 15 indexed citations
6.
Zecchetto, Camilla, Valeria Merz, Silvia Pietrobono, et al.. (2023). Targeting FGFR Pathway Is Not an Effective Therapeutic Strategy in Patients with Unselected Metastatic Esophagogastric Cancer Resistant to Trastuzumab. Journal of Personalized Medicine. 13(3). 508–508. 1 indexed citations
7.
Conci, Simone, Giovanni Catalano, Camilla Zecchetto, et al.. (2023). Current Role and Future Perspectives of Immunotherapy and Circulating Factors in Treatment of Biliary Tract Cancers. International Journal of Medical Sciences. 20(7). 858–869. 5 indexed citations
8.
Bencivenga, Maria, Lorena Torroni, Camilla Zecchetto, et al.. (2023). YAP Activation Is Associated with a Worse Prognosis of Poorly Cohesive Gastric Cancer. Journal of Personalized Medicine. 13(9). 1294–1294. 1 indexed citations
9.
Merz, Valeria, Carlo Messina, Camilla Zecchetto, et al.. (2023). Is There Room for Liposomal Irinotecan in Biliary Tract Cancer? A Meta-analysis of Randomised Trials. Clinical Oncology. 36(2). 87–97. 2 indexed citations
10.
Merz, Valeria, Camilla Zecchetto, Silvia Pietrobono, et al.. (2022). Predictive Biomarkers for a Personalized Approach in Resectable Pancreatic Cancer. Frontiers in Surgery. 9. 866173–866173. 5 indexed citations
11.
Merz, Valeria, Camilla Zecchetto, Alessandro Cavaliere, et al.. (2021). Targeting KRAS: The Elephant in the Room of Epithelial Cancers. Frontiers in Oncology. 11. 638360–638360. 44 indexed citations
12.
Melisi, Davide, Do‐Youn Oh, Antoine Hollebecque, et al.. (2021). Safety and activity of the TGFβ receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer. Journal for ImmunoTherapy of Cancer. 9(3). e002068–e002068. 149 indexed citations
13.
Merz, Valeria, Camilla Zecchetto, Raffaela Santoro, et al.. (2020). Plasma IL8 Is a Biomarker for TAK1 Activation and Predicts Resistance to Nanoliposomal Irinotecan in Patients with Gemcitabine-Refractory Pancreatic Cancer. Clinical Cancer Research. 26(17). 4661–4669. 19 indexed citations
14.
Silverman, Ian M., Antoine Hollebecque, Luc Friboulet, et al.. (2020). Clinicogenomic Analysis of FGFR2 -Rearranged Cholangiocarcinoma Identifies Correlates of Response and Mechanisms of Resistance to Pemigatinib. Cancer Discovery. 11(2). 326–339. 191 indexed citations breakdown →
15.
Merz, Valeria, Alessandro Cavaliere, Carlo Messina, et al.. (2020). Multicenter Retrospective Analysis of Second-Line Therapy after Gemcitabine Plus Nab-Paclitaxel in Advanced Pancreatic Cancer Patients. Cancers. 12(5). 1131–1131. 6 indexed citations
16.
Santoro, Raffaela, Marco Zanotto, Francesca Simionato, et al.. (2019). Modulating TAK1 Expression Inhibits YAP and TAZ Oncogenic Functions in Pancreatic Cancer. Molecular Cancer Therapeutics. 19(1). 247–257. 47 indexed citations
17.
Carbone, Carmine, Geny Piro, Valeria Merz, et al.. (2018). Angiopoietin-Like Proteins in Angiogenesis, Inflammation and Cancer. International Journal of Molecular Sciences. 19(2). 431–431. 161 indexed citations
18.
Carbone, Carmine, Geny Piro, Francesca Simionato, et al.. (2017). Homeobox B9 Mediates Resistance to Anti-VEGF Therapy in Colorectal Cancer Patients. Clinical Cancer Research. 23(15). 4312–4322. 41 indexed citations
19.
Melisi, Davide, Geny Piro, Francesca Simionato, et al.. (2017). A circulating TH2 cytokines profile predicts survival in patients with resectable pancreatic adenocarcinoma. Annals of Oncology. 28. v27–v27.
20.
Carbone, Carmine, Geny Piro, Francesca Ligorio, et al.. (2017). Adipocytes sustain pancreatic cancer progression through a non-canonical WNT paracrine network inducing ROR2 nuclear shuttling. International Journal of Obesity. 42(3). 334–343. 35 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Valeria Merz Breakdown of academic impact, for papers by Francesca Simionato Breakdown of academic impact, for papers by Alexandros Nomikos Breakdown of academic impact, for papers by Min Tu Breakdown of academic impact, for papers by Cinzia Puppin Breakdown of academic impact, for papers by Moubin Lin Breakdown of academic impact, for papers by Caisheng Ye Breakdown of academic impact, for papers by William O’Connor Breakdown of academic impact, for papers by Brett H. Herzog
Rankless by CCL
2026